LeMaitre Vascular, Inc. cash flow to debt ratio of 43.78% indicates that the company generates enough cash to cover its debts. This level indicates strong financial health.

LeMaitre Vascular, Inc.'s free cash flow has increased 100.39% from $37.16M last year to $74.47M, signaling increasing performance

LeMaitre Vascular, Inc.'s debt to equity ratio is 0.47, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.

LeMaitre Vascular, Inc.'s debt has decreased relative to shareholder equity from 0.55 last year to 0.47 today, signaling strengthened financials

LeMaitre Vascular, Inc. has a net debt to EBITDA ratio of 1.73x, which is below the 3.00x threshold, indicating healthy leverage and financial stability

LeMaitre Vascular, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

LeMaitre Vascular, Inc.'s profit margin has increased (21.56%) in the last year from 20.03% to 24.35%, signaling increasing performance

LeMaitre Vascular, Inc.'s short-term assets of $468.23M exceed its short-term liabilities of $36.32M

LeMaitre Vascular, Inc.'s return on assets of 9.91% is higher than the 5.00% threshold, indicating efficient asset utilization

LeMaitre Vascular, Inc.'s return on equity of 16.19%, is higher than 15.00%, indicating good performance

LeMaitre Vascular, Inc.'s operating cash flow exceeds its net income, indicating high-quality earnings backed by actual cash generation

LeMaitre Vascular, Inc. had positive net income in 5.00 out of 5 years, indicating stable and consistent earnings

LeMaitre Vascular, Inc. has positive free cash flow, indicating the company generates cash after capital expenditures

LeMaitre Vascular, Inc. has a free cash flow yield of 3.33%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

LeMaitre Vascular, Inc.'s yearly earnings has increased 31.10% since last year from $44.04M to $57.73M, signaling increasing performance

LeMaitre Vascular, Inc.'s yearly revenue has increased 13.53% since last year from $219.86M to $249.60M, signaling increasing performance

ROIC 9.43% (Source: FMP key-metrics). In the 5–10% partial-credit band. Score: 1 of 2. This band sits within the typical US weighted-average cost of capital range. Methodology choice can change the conclusion: under FMP's invested-capital definition the company is at or near its cost of capital; under narrower operating-capital definitions the same company may score higher. Invested capital here includes equity, non-current liabilities, and short-term debt. Cash is not subtracted. See methodology.

LeMaitre Vascular, Inc.'s 3-year revenue CAGR of 15.58% is positive, indicating growing revenue over the past 3 years

LeMaitre Vascular, Inc. had revenue growth in 5.00 out of 5 years, indicating consistent revenue performance

LeMaitre Vascular, Inc. had positive ROE in 5.00 out of 5 years, indicating consistent and reliable returns on equity

LeMaitre Vascular, Inc. is overvalued relative to its fair value price of 51.13 based on Discounted Cash Flow model

LeMaitre Vascular, Inc. has an earnings yield of 2.80%, which is below the 4.00% threshold, indicating the stock may be expensive relative to its earnings

LeMaitre Vascular, Inc. is overvalued relative to its fair value price of 21.00 based on EBITDA multiple model

LeMaitre Vascular, Inc. has an EV/EBITDA ratio of 26.36x, which exceeds the 20.00x threshold, indicating the stock may be overvalued relative to its operating earnings

LeMaitre Vascular, Inc. is overvalued relative to its fair value price of 46.85 based on Earnings Fair Value model

LeMaitre Vascular, Inc. has a PEG-ratio over 1 which is considered overvalued

LeMaitre Vascular, Inc. has a price-to-book ratio of 5.49x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

LeMaitre Vascular, Inc. has a price-to-sales ratio of 8.71x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue